<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665626</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-011</org_study_id>
    <nct_id>NCT00665626</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)</brief_title>
  <acronym>Taski-3</acronym>
  <official_title>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor,
      R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment
      of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology 20 (ACR20) Response at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP or ESR, after 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 50 (ACR50) Response at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 70 (ACR70) Response at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Index of Improvement (ACRn) at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 3 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score-C-Reactive Protein (DAS28-CRP) &lt;2.6 at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score-C-Reactive Protein (DAS28-CRP) &lt;3.2 at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) &lt;2.6 at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) &lt;3.2 at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 20 (ACR20) Response at Week 1</measure>
    <time_frame>1 week</time_frame>
    <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 1 week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 20 (ACR20) Response at Week 2</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Erosion Score at 3 Months</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change from baseline in RAMRIS erosion score (a measure of bone erosion in the hands and wrists), calculated as the score at 3 months minus the score at baseline. The erosion score runs from 0 to 250 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Osteitis Score at 3 Months</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change from baseline in RAMRIS osteitis score (a measure of bone inflammation in the hands and wrists), calculated as the score at 3 months minus the score at baseline. The osteitis score runs from 0 to 75 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Synovitis Score at 3 Months</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change from baseline in RAMRIS synovitis score (a measure of inflammation in the joints of the hands and wrists), calculated as the score at 3 months minus the score at baseline. The synovitis score runs from 0 to 24 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) &gt;1.5x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with ALT (a test of liver function) values greater than 1.5 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) &gt;1.5-2x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with ALT (a test of liver function) values greater than 1.5 to 2 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) &gt;2-3x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with ALT (a test of liver function) values greater than 2 to 3 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) &gt;3x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with ALT (a test of liver function) values greater than 3 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) &gt;3-5x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with ALT (a test of liver function) values greater than 3 to 5 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) &gt;5-10x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with ALT (a test of liver function) values greater than 5 to 10 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) &gt;10x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with ALT (a test of liver function) values greater than 10 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) &gt;1.5x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with AST (a test of liver function) values greater than 1.5 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) &gt;1.5-2x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with AST (a test of liver function) values greater than 1.5 to 2 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) &gt;2-3x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with AST (a test of liver function) values greater than 2 to 3 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) &gt;3x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with AST (a test of liver function) values greater than 3 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) &gt;3-5x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with AST (a test of liver function) values greater than 3 to 5 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) &gt;5-10x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with AST (a test of liver function) values greater than 5 to 10 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) &gt;10x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with AST (a test of liver function) values greater than 10 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase &gt;1.5x Upper Limit of Normal (ULN) and &gt;1.5x Baseline</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with alkaline phosphatase (a test of liver function) values greater than 1.5 times the ULN and greater than 1.5 times baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin &gt;1.5x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with bilirubin (a test of liver function) values greater than 1.5 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin &gt;2x Upper Limit of Normal (ULN)</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with bilirubin (a test of liver function) values greater than 2 times the ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Neutrophil Count (ANC) &lt;1500/mm3</measure>
    <time_frame>Any time between baseline and 3 months</time_frame>
    <description>The number of participants with ANC values less than 1500/mm3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, orally, twice-a-day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib disodium (R935788)</intervention_name>
    <description>R935788 100 mg tablet, orally, twice-a-day</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, orally, twice-a-day</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must give written informed consent by signing an IRB/EC-approved Informed
             Consent Form (ICF) prior to admission to this study.

          -  Males and females, 18 years of age or older, with active RA for at least 12 months
             prior to Day 1 dosing

          -  Are currently receiving or previously had received a biologic therapy with an
             inhibitor of TNF, rituximab, abatacept, or anakinra at an approved labeled dose for â‰¥3
             months prior to Day 1 dosing and are designated as biologic therapy failures for lack
             of efficacy, safety, or tolerability.

          -  Patients may receive stable doses of methotrexate (MTX), azathioprine (not in
             combination with MTX), leflunomide (not in combination with MTX), sulfasalazine,
             chloroquine, hydroxychloroquine, gold, NSAIDs (including COX2 inhibitors),
             minocycline, or doxycycline. The dose must have been stable for at least 30 days prior
             to Day 1 dosing and must not be changed during the washout, screening and treatment
             periods, unless dictated by tolerability requirements. Patients who are taking MTX
             must have been receiving weekly MTX doses (7.5-25 mg/week) for a minimum of 3 months
             prior to Day 1 dosing and must be receiving a stable MTX dose, with no change in
             route, for the previous 6 weeks prior to Day 1 dosing. Patients who are receiving MTX
             must also be receiving folic or folinic acid supplementation at a stable dose for at
             least 6 weeks prior to Day 1 dosing.

          -  Females of childbearing potential must be fully informed of the potential for R788 to
             adversely affect the fetus and, if sexually active, must agree to use a well
             established method of birth control during the study (oral contraceptive, mechanical
             barrier, long acting hormonal agent). These patients must not be lactating and must
             have a negative urine pregnancy test at the time of randomization and at each
             laboratory determination.

          -  The patient must otherwise be in good health as determined by the Investigator on the
             basis of medical history, physical examination, and laboratory screening tests during
             the screening period. See exclusion criteria for specific exclusions.

          -  In the Investigator's opinion, the patient has the ability to understand the nature of
             the study and any hazards of participation, and to communicate satisfactorily with the
             Investigator and to participate in, and to comply with, the requirements of the entire
             protocol.

        Exclusion Criteria:

          -  The patient has a history of, or a concurrent, clinically significant illness, medical
             condition (other than arthritis) or laboratory abnormality that, in the Investigator's
             opinion, could affect the conduct of the study. Specifically, excluded are patients
             with the following:

               1. uncontrolled or poorly controlled hypertension;

               2. other autoimmune disease (psoriatic arthritis, lupus, mixed connective disorder)
                  or arthritis syndromes (gout, Lyme disease, Reiter's syndrome);

               3. recent serious surgery or infectious disease;

               4. recent history ( of, or treatment for, a malignancy other than nonmelanomatous
                  skin cancer, or any history of lymphoma;

               5. Hepatitis B;

               6. Hepatitis C;

               7. interstitial pneumonitis or active pulmonary infection on chest x-ray

               8. Tuberculosis (TB)

               9. known laboratory abnormalities

          -  The patient has a history of substance abuse, drug addiction or alcoholism. Patients
             may consume up to 4 units of alcohol per week; however, alcohol should be avoided in
             the 72 hours prior to lab assessments. Patients who cannot reliably comply with this
             should be excluded. A unit of alcohol is defined as the following: Beer=12 oz or 355
             mL; wine = 5 oz or 148 mL; sweet dessert wine=3 oz or 89 mL; 80 proof distilled
             spirits= 1.5 oz or 44 mL.

          -  The patient has been treated previously treated with R788 under a different protocol.

          -  The patient has a pacemaker, aneurysm clip or other contraindication to MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel B Magilavy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rigel Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>California</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Arthritis &amp; Medical Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RASF-Clinical Research Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Research Institute</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddock Park Clinical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Orthopedics</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates, SC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Group Clinical Research Inst</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Arthritis &amp; Osteoperosis</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <zip>42701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Osteoporosis &amp; Clinical Trials Center</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Osteoporosis &amp; Clinical Trials Center</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiechtner Research, Inc.</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westroads Medical Group</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewich Health System</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrew Porges, MD PC</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Long Island</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Division</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading, LLP</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Rheumatology &amp; Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwepen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumalab S.A.</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologos del Caribe</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIREEM</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Renato Guzman</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A.</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum am Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologia Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria della Miseri</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ginecologia y Reproduccion</name>
      <address>
        <city>Lima</city>
        <zip>33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Peru</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <results_first_submitted>June 6, 2016</results_first_submitted>
  <results_first_submitted_qc>June 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2016</results_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant received the first dose of study drug on 28 May 2008; the last participant completed the study on 09 June 2009. Participants were recruited from centers in the United States, Europe and Latin America.</recruitment_details>
      <pre_assignment_details>Male/female participants who had active rheumatoid arthritis (RA) for a minimum of 12 months and who had failed prior biologic therapy were randomly assigned to receive R788 100 mg twice daily or placebo. It was planned to randomize approximately 195 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
        </group>
        <group group_id="P2">
          <title>R788 100 mg Bid</title>
          <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73">Participants randomized</participants>
                <participants group_id="P2" count="146">Participants randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63">Participants completed the study</participants>
                <participants group_id="P2" count="124">Participants completed the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not fulfil inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unably to comply with dosing regimen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
        </group>
        <group group_id="B2">
          <title>R788 100 mg Bid</title>
          <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="146"/>
            <count group_id="B3" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="12.29"/>
                    <measurement group_id="B2" value="56.0" spread="11.45"/>
                    <measurement group_id="B3" value="56.0" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American College of Rheumatology 20 (ACR20) Response at 3 Months</title>
        <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP or ESR, after 3 months</description>
        <time_frame>3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 20 (ACR20) Response at 3 Months</title>
          <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP or ESR, after 3 months</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 50 (ACR50) Response at 3 Months</title>
        <description>The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 3 months</description>
        <time_frame>3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 50 (ACR50) Response at 3 Months</title>
          <description>The number of participants with greater than or equal to 50% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 3 months</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 70 (ACR70) Response at 3 Months</title>
        <description>The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 3 months</description>
        <time_frame>3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 70 (ACR70) Response at 3 Months</title>
          <description>The number of participants with greater than or equal to 70% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 3 months</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology Index of Improvement (ACRn) at 3 Months</title>
        <description>The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 3 months of treatment</description>
        <time_frame>3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology Index of Improvement (ACRn) at 3 Months</title>
          <description>The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA after 3 months of treatment</description>
          <population>Intent-to-treat population</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.85" spread="25.604"/>
                    <measurement group_id="O2" value="25.95" spread="28.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score-C-Reactive Protein (DAS28-CRP) &lt;2.6 at 3 Months</title>
        <description>Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms</description>
        <time_frame>3 months</time_frame>
        <population>Intent-to-Treat Population with CRP as Primary Phase Reactant</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score-C-Reactive Protein (DAS28-CRP) &lt;2.6 at 3 Months</title>
          <description>Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms</description>
          <population>Intent-to-Treat Population with CRP as Primary Phase Reactant</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score-C-Reactive Protein (DAS28-CRP) &lt;3.2 at 3 Months</title>
        <description>Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity.</description>
        <time_frame>3 months</time_frame>
        <population>Intent-to-Treat Population with CRP as Primary Phase Reactant</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score-C-Reactive Protein (DAS28-CRP) &lt;3.2 at 3 Months</title>
          <description>Number of participants with DAS28-CRP (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and CRP in patients with high CRP at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity.</description>
          <population>Intent-to-Treat Population with CRP as Primary Phase Reactant</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) &lt;2.6 at 3 Months</title>
        <description>Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms</description>
        <time_frame>3 months</time_frame>
        <population>Intent-to-Treat Population with ESR as Primary Phase Reactant</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) &lt;2.6 at 3 Months</title>
          <description>Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 2.6. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 2.6 indicates remission of RA symptoms</description>
          <population>Intent-to-Treat Population with ESR as Primary Phase Reactant</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) &lt;3.2 at 3 Months</title>
        <description>Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity.</description>
        <time_frame>3 months</time_frame>
        <population>Intent-to-Treat Population with ESR as Primary Phase Reactant</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) &lt;3.2 at 3 Months</title>
          <description>Number of participants with DAS28-ESR (measuring RA symptoms including: tender joint count, swollen joint count, patient's assessment of disease activity, and ESR in patients with high ESR at baseline), of less than 3.2. The DAS runs from 0 to 10 - higher scores indicate worse symptoms. A score of less than 3.2 indicates low disease activity.</description>
          <population>Intent-to-Treat Population with ESR as Primary Phase Reactant</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 20 (ACR20) Response at Week 1</title>
        <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 1 week.</description>
        <time_frame>1 week</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 20 (ACR20) Response at Week 1</title>
          <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 1 week.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 20 (ACR20) Response at Week 2</title>
        <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 2 weeks</description>
        <time_frame>2 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 20 (ACR20) Response at Week 2</title>
          <description>The number of participants with greater than or equal to 20% improvement in tender and swollen joint counts, AND in any 3 of the following: physician's assessment of disease activity, patient's assessment of disease activity, patient's assessment of pain, HAQ-DI; and CRP or ESR, whichever was elevated at baseline, after 2 weeks</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Erosion Score at 3 Months</title>
        <description>Change from baseline in RAMRIS erosion score (a measure of bone erosion in the hands and wrists), calculated as the score at 3 months minus the score at baseline. The erosion score runs from 0 to 250 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>Intent-to-treat population with available data and received study drug. The discrepancy in the lower number of subjects than those in the ITT population is because 43 subjects either never had a complete set of MRIs (pre and post-study) or had uninterpretable results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Erosion Score at 3 Months</title>
          <description>Change from baseline in RAMRIS erosion score (a measure of bone erosion in the hands and wrists), calculated as the score at 3 months minus the score at baseline. The erosion score runs from 0 to 250 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
          <population>Intent-to-treat population with available data and received study drug. The discrepancy in the lower number of subjects than those in the ITT population is because 43 subjects either never had a complete set of MRIs (pre and post-study) or had uninterpretable results.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.740"/>
                    <measurement group_id="O2" value="0.78" spread="2.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Osteitis Score at 3 Months</title>
        <description>Change from baseline in RAMRIS osteitis score (a measure of bone inflammation in the hands and wrists), calculated as the score at 3 months minus the score at baseline. The osteitis score runs from 0 to 75 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>Intent-to-treat population with available data and received study drug. The discrepancy in the lower number of subjects than those in the ITT population is because 43 subjects either never had a complete set of MRIs (pre and post-study) or had uninterpretable results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Osteitis Score at 3 Months</title>
          <description>Change from baseline in RAMRIS osteitis score (a measure of bone inflammation in the hands and wrists), calculated as the score at 3 months minus the score at baseline. The osteitis score runs from 0 to 75 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
          <population>Intent-to-treat population with available data and received study drug. The discrepancy in the lower number of subjects than those in the ITT population is because 43 subjects either never had a complete set of MRIs (pre and post-study) or had uninterpretable results.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="4.848"/>
                    <measurement group_id="O2" value="-0.19" spread="5.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Synovitis Score at 3 Months</title>
        <description>Change from baseline in RAMRIS synovitis score (a measure of inflammation in the joints of the hands and wrists), calculated as the score at 3 months minus the score at baseline. The synovitis score runs from 0 to 24 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>Intent-to-treat population with available data and received study drug. The discrepancy in the lower number of subjects than those in the ITT population is because 43 subjects either never had a complete set of MRIs (pre and post-study) or had uninterpretable results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Synovitis Score at 3 Months</title>
          <description>Change from baseline in RAMRIS synovitis score (a measure of inflammation in the joints of the hands and wrists), calculated as the score at 3 months minus the score at baseline. The synovitis score runs from 0 to 24 with lower values indicating a better clinical condition. A negative change indicates an improvement in symptoms.</description>
          <population>Intent-to-treat population with available data and received study drug. The discrepancy in the lower number of subjects than those in the ITT population is because 43 subjects either never had a complete set of MRIs (pre and post-study) or had uninterpretable results.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="1.791"/>
                    <measurement group_id="O2" value="-0.52" spread="2.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) &gt;1.5x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with ALT (a test of liver function) values greater than 1.5 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) &gt;1.5x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with ALT (a test of liver function) values greater than 1.5 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) &gt;1.5-2x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with ALT (a test of liver function) values greater than 1.5 to 2 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) &gt;1.5-2x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with ALT (a test of liver function) values greater than 1.5 to 2 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) &gt;2-3x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with ALT (a test of liver function) values greater than 2 to 3 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) &gt;2-3x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with ALT (a test of liver function) values greater than 2 to 3 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) &gt;3x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with ALT (a test of liver function) values greater than 3 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) &gt;3x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with ALT (a test of liver function) values greater than 3 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) &gt;3-5x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with ALT (a test of liver function) values greater than 3 to 5 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) &gt;3-5x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with ALT (a test of liver function) values greater than 3 to 5 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) &gt;5-10x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with ALT (a test of liver function) values greater than 5 to 10 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) &gt;5-10x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with ALT (a test of liver function) values greater than 5 to 10 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) &gt;10x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with ALT (a test of liver function) values greater than 10 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) &gt;10x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with ALT (a test of liver function) values greater than 10 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) &gt;1.5x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with AST (a test of liver function) values greater than 1.5 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) &gt;1.5x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with AST (a test of liver function) values greater than 1.5 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) &gt;1.5-2x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with AST (a test of liver function) values greater than 1.5 to 2 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) &gt;1.5-2x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with AST (a test of liver function) values greater than 1.5 to 2 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) &gt;2-3x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with AST (a test of liver function) values greater than 2 to 3 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) &gt;2-3x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with AST (a test of liver function) values greater than 2 to 3 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) &gt;3x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with AST (a test of liver function) values greater than 3 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) &gt;3x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with AST (a test of liver function) values greater than 3 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) &gt;3-5x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with AST (a test of liver function) values greater than 3 to 5 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) &gt;3-5x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with AST (a test of liver function) values greater than 3 to 5 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) &gt;5-10x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with AST (a test of liver function) values greater than 5 to 10 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) &gt;5-10x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with AST (a test of liver function) values greater than 5 to 10 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) &gt;10x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with AST (a test of liver function) values greater than 10 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) &gt;10x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with AST (a test of liver function) values greater than 10 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alkaline Phosphatase &gt;1.5x Upper Limit of Normal (ULN) and &gt;1.5x Baseline</title>
        <description>The number of participants with alkaline phosphatase (a test of liver function) values greater than 1.5 times the ULN and greater than 1.5 times baseline</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase &gt;1.5x Upper Limit of Normal (ULN) and &gt;1.5x Baseline</title>
          <description>The number of participants with alkaline phosphatase (a test of liver function) values greater than 1.5 times the ULN and greater than 1.5 times baseline</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin &gt;1.5x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with bilirubin (a test of liver function) values greater than 1.5 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin &gt;1.5x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with bilirubin (a test of liver function) values greater than 1.5 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin &gt;2x Upper Limit of Normal (ULN)</title>
        <description>The number of participants with bilirubin (a test of liver function) values greater than 2 times the ULN</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin &gt;2x Upper Limit of Normal (ULN)</title>
          <description>The number of participants with bilirubin (a test of liver function) values greater than 2 times the ULN</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Neutrophil Count (ANC) &lt;1500/mm3</title>
        <description>The number of participants with ANC values less than 1500/mm3</description>
        <time_frame>Any time between baseline and 3 months</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - R788 100 mg Bid</title>
            <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Neutrophil Count (ANC) &lt;1500/mm3</title>
          <description>The number of participants with ANC values less than 1500/mm3</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo to R788, oral tablets, twice daily, double-blind</description>
        </group>
        <group group_id="E2">
          <title>R788 100 mg Bid</title>
          <description>R788 100 mg, oral tablets, twice daily, double-blind</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne-Marie Duliege, MD</name_or_title>
      <organization>Rigel</organization>
      <phone>650-624-1100</phone>
      <email>clinicaltrials@rigel.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

